BTIG Maintains Buy on Lucid Diagnostics, Raises Price Target to $2.5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Mark Massaro maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $2 to $2.5.
BTIG analyst Mark Massaro maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $2 to $2.5.